Literature DB >> 9527815

Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro.

S P Tucker1, T R Stiebel, K E Potts, M L Smidt, M L Bryant.   

Abstract

The frequency of drug-resistant human immunodeficiency virus type 1 (HIV-1) variants in virus populations not previously exposed to drug was determined in vitro by using HIV-1RF and the protease inhibitor SC-55389A. Two variants with single mutations responsible for drug resistance (V82A and N88S) were quantifiably isolated after only one round of replication, yielding a crude frequency estimate of at least 1 SC-55389A-resistant variant per 3.5 x 10(5) wild-type infectious units.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9527815      PMCID： PMC105443          DOI： 10.1128/AAC.42.2.478

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  The HIV-1 protease as a therapeutic target for AIDS.

Authors:  C Debouck
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

2.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

3.  Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.

Authors:  D P Getman; G A DeCrescenzo; R M Heintz; K L Reed; J J Talley; M L Bryant; M Clare; K A Houseman; J J Marr; R A Mueller
Journal:  J Med Chem       Date:  1993-01-22       Impact factor: 7.446

4.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

5.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

Review 6.  Structure-based inhibitors of HIV-1 protease.

Authors:  A Wlodawer; J W Erickson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

7.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

8.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  SC-52151, a novel inhibitor of the human immunodeficiency virus protease.

Authors:  M Bryant; D Getman; M Smidt; J Marr; M Clare; R Dillard; D Lansky; G DeCrescenzo; R Heintz; K Houseman
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191
View more
  3 in total

1.  A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.

Authors:  R Ziermann; K Limoli; K Das; E Arnold; C J Petropoulos; N T Parkin
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Authors:  Wolfgang Resch; Rainer Ziermann; Neil Parkin; Andrea Gamarnik; Ronald Swanstrom
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

3.  Optimal drug synergy in antimicrobial treatments.

Authors:  Joseph Peter Torella; Remy Chait; Roy Kishony
Journal:  PLoS Comput Biol       Date:  2010-06-03       Impact factor: 4.475
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.